A Phase IV Post Approval Clinical Study of ExAblate Treatment of Metastatic Bone Tumors for the Palliation of Pain

The study hypotheses is that the proportion of patients experiencing clinically significant pain relief will be at least 30% greater than the proportion experiencing worsening pain.

Study Overview

• Status: Completed
• Conditions: Bone Metastasis
• Intervention / Treatment: Device: ExAblate MRgFUS

Detailed Description

As part of the PMA # P110039 review process and approval, InSightec was requested to conduct a post-approval study. Patients will be treated following the approved commercial treatment guidelines.

For this study, participating sites will use the ExAblate device for the administration of the ExAblate treatment. This study will be performed on either 1.5T or 3T MR scanners.

For this study, a total of 70 patients meeting the approved commercial guidelines will be enrolled and treated with the ExAblate system at from 7 to 10 sites. The proportion of responders is expected to be at least 30% greater than the proportion of subjects experiencing pain progression (i.e., 60% vs. 30%). Additionally, at the 3 month visit, an analysis of both the safety and efficacy profiles will be compared to the original PMA pivotal study group.

• Study Type: Interventional
• Enrollment (Actual): 32
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • California
    • Duarte, California, United States, 91010
      • City of Hope
    • Los Angeles, California, United States, 90024
      • University of California Los Angeles
    • San Francisco, California, United States, 94107
      • University of California San Francisco
    • Stanford, California, United States, 94305
      • Stanford University School of Medicine
  • Minnesota
    • Rochester, Minnesota, United States, 55905
      • Mayo Clinic
  • New York
    • New York, New York, United States, 10065
      • Weill Cornell Medical Center
  • Pennsylvania
    • Philadelphia, Pennsylvania, United States, 19111
      • Fox Chase Cancer Center
  • Texas
    • Houston, Texas, United States, 77030
      • MD Anderson
  • Virginia
    • Charlottesville, Virginia, United States, 22908
      • University of Virginia

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Men and women age 18 and older
• Patients who are able and willing to give consent and able to attend all study visits
• Patients who are suffering from symptoms of bone metastases or multiple myeloma bone lesions:
• Patients who have received radiation without adequate relief from metastatic bone pain as determined by the patient and treating physician
• those for whom their treating physician would not prescribe radiation or additional radiation treatments
• patients who refuse additional radiation therapy.
• Patient with NRS (0-10 scale) pain score ≥ 4 irrespective of medication
• Targeted bone/tumor interface are ExAblate device accessible and are located in ribs, extremities (excluding joints), pelvis, shoulders and in the posterior aspects of the following spinal vertebra: Lumbar vertebra (L3 - L5), Sacral vertebra (S1 - S5)
• Targeted bone/tumor interface (most painful lesion) size up to 55 cm2 in surface area
• Patient whose targeted (treated) lesion is on bone and the interface between the bone and lesion is deeper than 10-mm from the skin.
• Targeted (treated) tumor clearly visible by non-contrast MRI, and ExAblate MRgFUS device accessible
• Able to communicate sensations during the ExAblate treatment

• Patients on ongoing chemotherapy regimen at the time of eligibility:

  1. with same chemotherapy regime (as documented from patient medical dossier), And
  2. Worst pain NRS still ≥ 4 And
  3. do NOT plan to initiate a new chemotherapy for pain palliation should be eligible for the study.

Note: Planned multiple courses of chemotherapy are not considered New Chemotherapy.

• No radiation therapy to targeted (most painful) lesion in the past two weeks Bisphosphonate intake should remain stable throughout the study duration.
• Patients will have from 1 to 5 painful lesions and only the most painful lesion will be treated.
• Patients with persistent distinguishable pain associated with 1 site to be treated (if patient has pain from additional sites, the pain from the additional sites must be evaluated as being less intense by at least 2 points on the NRS compared to the site to be treated).

Exclusion Criteria:

• Patients who either
• Need surgical stabilization of the affected bony structure (>7 fracture risk score, see Section 7.4) OR
• Targeted tumor is at an impending fracture site (>7 on fracture risk score, see Section 7.4).

OR

• Patients with surgical stabilization of tumor site with metallic hardware
• More than 5 painful lesions, or more than 1 requiring immediate localized treatment
• Targeted (treated) tumor is in the skull
• Patients on dialysis
• Patients with life expectancy < 3-Months
• Patients with an acute medical condition (e.g., pneumonia, sepsis) that is expected to hinder them from completing this study.
• Patients with unstable cardiac status including:
• Unstable angina pectoris on medication
• Patients with documented myocardial infarction within six months of protocol entry
• Congestive heart failure requiring medication (other than diuretic)
• Patients on anti-arrhythmic drugs
• Severe hypertension (diastolic BP > 100 on medication)
• Patients with standard contraindications for MR imaging such as non-MRI compatible implanted metallic devices including cardiac pacemakers, size limitations, etc.
• Patients with an active infection or severe hematological, neurological, or other uncontrolled disease.
• Known intolerance or allergies to the MRI contrast agent (e.g. Gadolinium or Magnevist) including advanced kidney disease
• KPS Score < 60 (See "Definitions" below)
• Severe cerebrovascular disease (multiple CVA or CVA within 6 months)
• Individuals who are not able or willing to tolerate the required prolonged stationary position during treatment (approximately 2 hrs.)
• Target (treated) tumor is less then 1cm from nerve bundles, bowels or bladder.
• Are participating or have participated in another clinical trial in the last 30 days
• Patients initiating a new chemotherapy regime for pain purposes only, or radiation (for the targeted most painful lesion) within the last 2 weeks Note: Planned multiple courses of chemotherapy are not considered New Chemotherapy.
• Patients unable to communicate with the investigator and staff.
• Patients with persistent undistinguishable pain (pain source unidentifiable of the targeted lesion)
• Patient whose bone-lesion interface is < 10-mm from the skin
• Targeted (most painful) tumor NOT visible by non-contrast MRI,
• Targeted (most painful) tumor Not accessible to ExAblate
• The targeted tumor is less than 2 points more painful compared to other painful lesions on the site specific NRS.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Supportive Care
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: ExAblate Test Arm; Focused Ultrasound Surgery delivered by ExAblate MRgFUS	Device: ExAblate MRgFUS; Focused Ultrasound Ablation; Other Names: Magnetic Resonance guided Focused Ultrasound Surgery

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Proportion of Responders	The statistical hypothesis is that the proportion of responders will be significantly greater than the proportion of subjects experiencing pain progression (worsened pain or increased pain medications usage). Using the Numerical Rating Score (NRS) for pain (0 being no pain and 10 being worst imaginable pain), subjects were rated as a Responder or as having Pain Progression. A responder is defined as a subject with a reduction in NRS worst score from baseline of two (2) or more points, and no increase in pain medication use. Pain Progression was increased pain of two (2) or more points.	Three months post treatment

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety Profile	A full safety profile will be developed for the ExAblate treatment of bone metastases. All adverse events will be captured and summarized as defined in Section-6.2. Adverse events (type, frequency, severity) are expected to be similar to those captured for the original PMA study (PMA # P110039). For his study, the Safety comparison will be descriptive with no statistical endpoints.	Three Months

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Numerical Rating Scale (NRS) for Pain Score	Patient pain intensity on an 11-point Numerical Rating Scale from 0 to 10 in which 0 is no pain and 10 is the worst pain you can imagine. The NRS was administered pre-treatment and post-treatment. The trajectory of change was presented graphically.	Three months post treatment
Quality of Life (QOL) as Measured by Change in Brief Pain Inventory - Interference (BPI) From Baseline	The BPI-QOL questionnaire is designed to show the severity and interference of pain in the lives of patients. This is a 7-item questionnaire that asks respondents the extent to which pain interferes with their general activity, mood, walking ability, normal work, relations with other people, sleep and enjoyment of life using a 0-10 numerical rating scale in which 0 represents 'does not interfere' and 10 indicates 'completely interferes'. Responses to the 7 items are averaged to form the pain interference scale score. Thus, the minimum possible is 0 and the maximum possible is 10 points. Lower scores are better, showing less interference in daily activities while higher scores show more interference and hence worse outcomes.	Baseline, 1 Month post treatment, 2 Month post treatment, 3 Month post treatment.

Collaborators and Investigators

• Sponsor: InSightec

Study record dates

Study Major Dates

• Study Start: September 1, 2013
• Primary Completion (Actual): January 14, 2022
• Study Completion (Actual): January 14, 2022

Study Registration Dates

• First Submitted: April 12, 2013
• First Submitted That Met QC Criteria: April 16, 2013
• First Posted (Estimate): April 17, 2013

Study Record Updates

• Last Update Posted (Actual): April 7, 2023
• Last Update Submitted That Met QC Criteria: April 6, 2023
• Last Verified: April 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms; Neoplasms by Site; Musculoskeletal Diseases; Bone Diseases; Bone Neoplasms
• Other Study ID Numbers: BM018; P110039/S2 (Other Identifier: FDA PMA Supplement)